Antiparasitic Therapy Research Articles

Literature Study: Babesiosis in Dogs in The Period of 2013-2023

Background: Babesiosis is an infectious disease caused by Babesia spp. with tick vectors Rhipicephalus sanguineus and Dermacentor margniatus (a tick-borne disease). Babesiosis transmission occurs through tick bites or blood transfusions. Diagnostic techniques involve the microscopic examination of blood smears, hematology, blood chemistry, and PCR laboratory analysis. Purpose: To determine the clinical symptoms, confirmation of diagnosis, and therapy used for babesiosis conditions in dogs. Method: Analysis was conducted on 22 literature cases of babesiosis in dogs with a publication period of 2013-2023. The analysis was carried out using the descriptive analysis method, a problem-solving procedure that describes the condition of the subject or object based on facts, characteristics, and any relationships between the phenomena being investigated. Qualitative research methods were used to examine natural object conditions, as a key instrument. Data source sampling was done purposively, the data collection techniques were combined, the data analysis was either inductive or qualitative, and qualitative research results emphasize meaning. Result: Dog patients with babesiosis have the highest prevalence of clinical symptoms, namely anorexia (62.5%), vomiting (33.3%), pyrexia (54.16%) lethargy (45.83%), brownish urination (29.16%), and ectoparasite infestation (29.16%). Confirmation of the diagnosis carried out included the microscopic examination of blood smears (100%), hematology (91.66%), blood chemistry (41.66%), and Polymerase Chain Reaction (PCR) (20.83%). The therapeutic management used included 3 combinations of antibiotics in 7 cases (31.81%), combination therapy of 2 antibiotics and an antiparasitic in 3 cases (13.63%), and combination therapy of 1 antibiotic and antiparasitic in 3 cases (13.63%). Conclusion: Antiparasitic therapy that can be used is imidocarb dipropionate, which works by inhibiting inositol in the erythrocytes infected with Babesia spp. and diminazene aceturate, which works by disrupting parasite DNA synthesis.

CASE REPORT: GIANT HYDATID CYST OF THE LIVER IN A YOUNG PATIENT: SURGICAL MANAGEMENT AND LONG-TERM FOLLOW-UP

Hydatid disease, caused by the parasite Echinococcus granulosus, remains a significant public health issue in endemic areas, especially in rural settings. This report presents the case of an 18-year-old female patient residing in a rural area, with no significant medical history, who developed a symptomatic hepatic hydatid cyst. The patient was treated surgically without preoperative antiparasitic therapy and was placed on postoperative albendazole. The case highlights the importance of timely surgical intervention and long-term follow-up to prevent recurrence.

Spinal hydatid disease-A case report: An uncommon differential diagnosis in LMICs

Background and Importance: With a 0.2–1% incidence, spinal hydatid disease is a very uncommon diagnosis. While it is uncommon in affluent nations, it should be taken into account when making a differential diagnosis for spinal cord compression syndrome, particularly in regions where it is prevalent. Case Presentation: We report a case of hydatid illness of the spine. A 52-year-old man presented with lower extremity discomfort and spastic paraparesis, trouble urinating, and back pain and edema. He had at the level of the 12th thoracic to third lumbar vertebrae (Th12-L3) with paraspinal extension. The patient was treated with four months of antiparasitic therapy and two surgical resections performed by general surgeons. Histological analysis showed pieces of fibrous tissue exhibiting granulomatous inflammation; however, no evidence of acid-resistant bacteria or PAS-positive chitin membrane was found. The existence of bacteria following therapy has not been confirmed by the parasitological investigation of the lesions. Clinical discussion: Primary spinal hydrodatidosis is a rare condition that affects about 0.2–1% of the population. Conclusion: Due to rarity of this disease, early discovery and timely treatment are critical, and this diagnosis should be considered when generating a differential diagnosis for spinal cord compression syndrome.

Severe neurological and ocular manifestations in paediatric patients with toxoplasmosis. Case-series study with review of the current literature

Toxoplasmosis, both congenital and postnatally acquired, is a parasitic disease caused by infection with the protozoan Toxoplasma gondii. The most serious manifestation of this disease is congenital toxoplasmosis, resulting from transplacental infection of the foetus during pregnancy. Retinochoroiditis, intracranial calcifications, and hydrocephalus are considered the classic triad of congenital toxoplasmosis. This article describes four cases of severe neurologic and ocular manifestations in paediatric patients diagnosed with toxoplasmosis. The main aim was to examine the nature of clinical presentation as well as to emphasise the necessity of properly administered antiparasitic therapy and underline the importance of prenatal screening to reduce the risk of congenital transmission to the foetus.

Current challenges in neurocysticercosis: recent data and where we are heading.

Neurocysticercosis (NCC) is still a significant contributor to neurological disease in vast regions of the world, and increasingly diagnosed in nonendemic countries because of travel and immigration from endemic settings. There is a need for clinicians in endemic and nonendemic regions to understand the complexities of its diagnosis and management. Recent information on the performance and use of available imaging and immunodiagnostic tools as well as antiparasitic and anti-inflammatory therapeutic regimes were assessed. Imaging and serology data should be assessed in the context of the specific type of NCC to improve diagnostic precision. In terms of therapeutic approaches, more controlled data is required on the efficacy and safety of combined antiparasitic therapy, and antiseizure and anti-inflammatory regimes should be optimized to minimize perilesional damage and reduce the risk of epilepsy.

Ivermectin: A Multifaceted Drug With a Potential Beyond Anti-parasitic Therapy.

Ivermectin was first discovered in the 1970s by Japanese microbiologist Satoshi Omura and Irish parasitologist William C. Campbell. Ivermectin has become a versatile pharmaceutical over the past 50 years. Ivermectin is a derivative of avermectin originally used to treat parasitic infections. Emerging literature has suggested that its role goes beyond this and may help treat inflammatory conditions, viral infections, and cancers. Ivermectin's anti-parasitic, anti-inflammatory, anti-viral, and anticancer effects were explored. Its traditional mechanism of action in parasitic diseases, such as scabies and malaria, rests on its ability to interfere with the glutamate-gated chloride channels in invertebrates and the lack of P-glycoprotein inmany parasites. More recently, it has been discovered that the ability of ivermectin to block the nuclear factor kappa-light-chain enhancer of the activated B (NF-κB) pathway that modulates the expression and production of proinflammatory cytokines is implicated in its role as an anti-inflammatory agent to treat rosacea. Ivermectin has also been evaluated for treating infections caused by viruses, such as SARS-CoV-2 and adenoviruses, through inhibition of viral protein transportation and acting on the importin α/β1 interface. It has also been suggested that ivermectin can inhibit the proliferation of tumorigenic cells through various pathways that lead to the management of certain cancers. The review aimed to evaluate its multifaceted effects and potential clinical applications beyond its traditional use as an anthelmintic agent.

Amoebic colitis and liver abscess: A rare case of autochthonous invasive infection due to Entamoeba histolytica

We report an unusual and confirmed case of invasive amebiasis in a non-endemic area where the source of infection remains unknown. During her admission, the patient developed amebic colitis and extraintestinal liver abscess with a favorable outcome following the antiparasitic therapy.

Multiple myeloma and Chagas disease: qPCR as a marker for preemptive antiparasitic therapy: a case reports series and review.

Multiple myeloma (MM) associated with Chagas disease is rarely described. This disease and its therapy suppress T cell and macrophage functions and increase regulatory T cell function, allowing the increase of parasitemia and the risk of Chagas Disease Reactivation (CDR). We aimed to analyze the role of conventional (cPCR) and quantitative Polymerase Chain Reaction (qPCR) for prospective monitoring of T. cruzi parasitemia, searching for markers of preemptive antiparasitic therapy in MM patients with Chagas disease. Moreover, we investigated the incidence and management of hematological diseases and CDR both inside and outside the transplant setting in the MEDLINE database. We found 293 studies and included 31 of them. Around 1.9-2.0% of patients with Chagas disease were reported in patients undergoing Stem Cell Transplantation. One case of CDR was described in eight cases of MM and Chagas disease. We monitored nine MM and Chagas disease patients, seven under Autologous Stem Cell Transplantation (ASCT), during 44.56±32.10 months (mean±SD) using parasitological methods, cPCR, and qPCR. From these patients, three had parasitemia. In the first, up to 256 par Eq/mL were detected, starting from 28 months after ASCT. The second patient dropped out and died soon after the detection of 161.0 par Eq/mL. The third patient had a positive blood culture. Benznidazole induced fast negativity in two cases; followed by notably lower levels in one of them. Increased T. cruzi parasitemia was related to the severity of the underlying disease. We recommend parasitemia monitoring by qPCR for early introduction of preemptive antiparasitic therapy to avoid CDR.

Вплив перенесених паразитарних інфекцій під час вагітності на імунну систему плода (огляд літератури)

Transmission of infections during pregnancy is known to alter the development and functioning of the fetus immune system, resulting in an inadequate immune response to common childhood infections and immunizations. Although it is a developing and actively researched topic, maternal parasitic infections remain poorly understood. Millions of women of reproductive age are currently at risk of parasite infection, while many pregnant, chronically infected women are excluded from mass drug administration due in part to a lack of resources, as well as fear of unknown adverse fetal outcomes. infection, there is no clear mechanism for understanding how maternal infection reprograms offspring immunity. Purpose - to determine the currently studied mechanisms of the influence of parasitic infections transmitted during pregnancy on the immune system of the fetus and to describe the possible effects of these influence in the long term on the health of children. Conclusions. The study of maternal parasitic infections is a rapidly developing field. Although infant mortality rates are declining, areas with endemic parasites still have the highest infant mortality rates. As antiparasitic therapy is not always curable, there is a critical need to understand the effects of maternal infection on offspring immune development. Due to the increased risk of immune alteration due to maternal inflammation and reduced passive antibody transmission, maternal parasitic infections and their mechanism of adverse immunomodulation must be uncovered to improve vaccination regimens and reduce childhood morbidity in endemic regions. No conflict of interests was declared by the author.

INCIDENCE OF INTESTINAL PARASITES IN CHILDREN WITH CHRONIC SPONTANEOUS URTICARIA

This study aimed to investigate the incidence of intestinal parasites in children who have been diagnosed with chronic spontaneous urticaria. A prospective control study was conducted at the Pathology Department of MMDC, Multan. The study included a total of 150 children, both from government and private schools. The children were divided into two groups: group A comprised 80 children diagnosed with chronic spontaneous urticaria, and group B included 70 healthy children. Group A was assessed for intestinal infections, and those with parasites were given anti-parasitic therapy. The outcomes were then evaluated. Out of the participants in group A, 18 (22.5%) had intestinal parasitic infections (IPI), compared to 10 (14.2%) in group B. Although the incidence of IPI was higher in group A, the difference was not statistically significant (P=.181). Blastocystis sp. was found in 14 (17.5%) patients in group A and 10 (14.2%) in group B. The eosinophil percentage in group A was 2% (.6% - 3.7%), and in group B was 1.5% (.6% - 2.2%) (P= .045). The total IgE value in group A was 97.6 IU/mL (ranging from 29-246 IU/mL), and in group B was 31.6 IU/mL (ranging from 14.2-65.8 IU/mL) (P <.001). Patients diagnosed with IPI were treated with metronidazole; out of the 18 patients, 10 (55.5%) saw an end to their urticaria symptoms. The results of this study suggest that Blastocystis sp. and D. fragilis were the most common parasites found in children with urticaria, which can disrupt their lifestyle.

Cysticercosis of the Neck Masquerading as Submandibular Swelling.

Cysticercus cellulosae is the larval form of Taenia solium. The disease is transmitted by faecoral route by consumption of eggs from contaminated food. Sonography & CT neck-well-defined, cystic lesion with hyperechoic area suggestive of a scolex. FNAC revealed non human like cells, fibrillation stroma, inflammatory cells. Treatment includes antiparasitic therapy, steroids.

An Iatrogenic Hepato-Peritoneal Hydatidosis Revealed at the Stage of Abdominal Cutaneous Fistula: A Case Report

Hydatidosis is a parasitic disease caused by the development of the larval form of Echinococcus granulosus, it is a significant public health problem in Morocco due to its frequency and the severity of some of its complications. Hepato-peritoneal hydatidosis is a rare serious condition, with a high risk of recurrence and significant morbidity and mortality. The peritoneal localization is most frequently iatrogenic caused by a previous hydatidosis surgery; the revelation by external abdomino-parietal fistulization makes it more uncommon. The large laparotomy surgery excision is the chosen treatment. Furthermore, to prevent possible recurrence a long-term antiparasitic therapy should be implemented. In our case, it was an intra-abdominal hydatid contamination due to the iatrogenic intraperitoneal rupture of the hepatic hydatidosis. This condition was revealed at the stage of cutaneious abdominal fistulization. The abdominal CT scan showed both positive and topographic diagnosis. our therapeutic strategy associated a large laparotomy surgery and antiparasitic medical treatment. The secondary peritoneal hydatidosis caused by iatrogenic trauma is rare but constitute a serious problem with short free recurrence disease and a high risk of morbi-mortality. This case illustrates the potential complication of hydatid cyst surgery, and the latency of the peritoneal localization.

Motile microfilaria captured by fluorescent microscopy and the unmasking of eosinophilia following treatment

A 24-year-old patient from Cameroon presented to our hospital because of a foreign structure in her left eye. To our knowledge, for the first time, fluorescent microscopy revealed motile microfilariae, and the diagnosis of loiasis was established. Despite substantial microfilaremia, eosinophilia only unmasked after the initiation of antiparasitic therapy.

Intraventricular Neurocysticercosis: Comparative Analysis of Different Localizations. Clinical Course and Treatment. A Systematic Review.

Background Neurocysticercosis is significant due to its high prevalence and considerable morbidity and mortality. The intraventricular form of NCC is less common than parenchymal, may have a rapidly progressive course and it requires a corresponding therapeutic response. Despite the extensive literature dealing with NCC and intraventricular cystic lesions, no systematic reviews have addressed similar work related to the clinical course and treatment of the infestation. Our main objective was to analyze the clinical type of the disease and the management for each ventricle separately on the basis of case reports or series of patients with individual data on the course of the disease and its treatment. As a control group, we used data on signs&symptoms and treatment of patients from published series on intraventricular neurocysticercosis. Method We performed a search in the Medline database. Google Scholar was also randomly searched. We extracted the following data from the eligible case/series: age and gender, symptoms, clinical signs, diagnostic examinations and findings, localization, treatment, follow-up period, outcome, and publication year. All data are presented in the form of absolute and relative numbers. The frequency of signs and symptoms, treatment and outcomes of the observed groups were checked by the Chi-square test and Fisher's test. The hypothesis was tested with p <0.05 as statistical significance. Results We selected 160 cases of intraventricular neurocysticercosis (IVNCC) and divided them according to their localization into five categories. Hydrocephalus was recognized in 134 cases (83.4%). Patients with isolated IVNCCare are younger (P=.0264) and have a higher percentage of vesicular cysts (p <.00001). In mixed IVNCC, degenerative and multiple confluent cysts predominate (p = 0.00068). Individuals carrying fourth + third ventricular cysts (potentially obstructive form) are younger than individuals with lateral ventricles (potentially less obstructive forme) (p = .0083). The majority of patients had individual symptoms for a longer period before the acute onset of the disease (p <.00001). The predominant clinical manifestation is headache (88.7%); the proportion within the groups ranged from 100% to 75% without statistical significance (p.074214). The same was true for patients with symptoms of vomiting or nausea, who had a lower and roughly balanced percentage of 67.7% to 44.4% (p.34702). Altered level of consciousness (ranging from 21% to 60%) and focal neurological deficit (from 51.2% to 15%) are the only clinical category with statistical significance (p <0.001 and p.023948 ). Other signs and symptoms were less frequent and statistically irrelevant. Surgical resection of the parasite was the predominant type of treatment, varying from 55.5% to 87.5% (p- .02395); endoscopy (48.2%) and craniotomy (24.4%), each individually, showed statistical significance (.00001 and .000073, respectively). The difference was also relevant among patients who had CSF diversion performance with/without medical treatment (p-.002312. Postoperatively, 31.8% of patients received anthelmintics with/without anti-inflammatory or other drugs. Endoscopy, open surgery, and postoperative antiparasitic therapy showed statistical differences (p < 0.001). Favorable outcomes or regression of symptoms were recorded in 83.7%, mortality 7.5%. In the case series, the clinical signs&symptoms were as follows: headache-64%, nausea and vomiting 48.4%, focal neurological deficit 33.6% and altered level of consciousness 25%. Open surgery was the predominant form of intervention (craniotomy (57.6% or endoscopy 31.8%); with statistical significance between them (p< .00001). Conclusion. Ventricular neurocysticercosis is an alarming clinical condition. Hydrocephalus is the dominant diagnostic sign. Isolated IVNCC patients were recognized at a younger age than Mix.IVNCC individuals; poeple with cysts in the fourth and third ventricles (as a potentially more occlusive type of disease), presented their symptoms at a younger age than individuals with LVNCC. The majority of patients had long-term signs and symptoms before the acute onset of the disease. Headache, nausea& vomiting are the most common symptoms of infestation accompanied by altered sensorium and focal neurological deficits. Surgery is the best treatment option. A sudden increase in ICP due to cerebrospinal fluid obstruction with a successive cerebral hernia is the leading cause of fatal outcomes.

Metallic Nanoparticles and Core-Shell Nanosystems in the Treatment, Diagnosis, and Prevention of Parasitic Diseases.

The usage of nanotechnology in the fight against parasitic diseases is in the early stages of development, but it brings hopes that this new field will provide a solution to target the early stages of parasitosis, compensate for the lack of vaccines for most parasitic diseases, and also provide new treatment options for diseases in which parasites show increased resistance to current drugs. The huge physicochemical diversity of nanomaterials developed so far, mainly for antibacterial and anti-cancer therapies, requires additional studies to determine their antiparasitic potential. When designing metallic nanoparticles (MeNPs) and specific nanosystems, such as complexes of MeNPs, with the shell of attached drugs, several physicochemical properties need to be considered. The most important are: size, shape, surface charge, type of surfactants that control their dispersion, and shell molecules that should assure specific molecular interaction with targeted molecules of parasites' cells. Therefore, it can be expected that the development of antiparasitic drugs using strategies provided by nanotechnology and the use of nanomaterials for diagnostic purposes will soon provide new and effective methods of antiparasitic therapy and effective diagnostic tools that will improve the prevention and reduce the morbidity and mortality caused by these diseases.

Phase II, Double-Blinded, Randomized, Placebo-Controlled Clinical Trial Investigating the Efficacy of Mebendazole in the Management of Symptomatic COVID-19 Patients.

The outbreak of the COVID-19 pandemic has spread throughout the world, affecting almost all nations and territories. The current double-blind, randomized, placebo-controlled, phase II clinical trial sought to evaluate the clinical efficacy and safety of mebendazole as an adjuvant therapy for outpatients with COVID-19. The patients were recruited and divided into two groups: a Mebendazole-treated group and placebo group. The mebendazole and placebo groups were matched for age, sex, and complete blood count (CBC) with differential and liver and kidney function tests at baseline. On the third day, the C-reactive protein (CRP) levels were lower (2.03 ± 1.45 vs. 5.45 ± 3.95, p < 0.001) and the cycle threshold (CT) levels were higher (27.21 ± 3.81 vs. 24.40 ± 3.09, p = 0.046) significantly in the mebendazole group than in the placebo group on the third day. Furthermore, CRP decreased and CT dramatically increased on day three compared to the baseline day in the mebendazole group (p < 0.001 and p = 0.008, respectively). There was a significant inverse correlation between lymphocytes and CT levels in the mebendazole group (r = -0.491, p = 0.039) but not in the placebo group (r = 0.051, p = 0.888). Mebendazole therapy increased innate immunity and returned inflammation to normal levels in COVID-19 outpatients faster than it did in the placebo group in this clinical trial. Our findings add to the growing body of research on the clinical and microbiological benefits of repurposing antiparasitic therapy, specifically mebendazole, for SARS-CoV-2 infection and other viral infections.

A novel antimicrobial peptide screened by a Bacillus subtilis expression system, derived from Larimichthys crocea Ferritin H, exerting bactericidal and parasiticidal activities.

Antimicrobial peptides (AMPs) may be the most promising substitute for antibiotics due to their effective antimicrobial activities and multiple function mechanisms against pathogenic microorganisms. In this study, a novel AMP containing 51 amino acids, named Lc1687, was screened from the large yellow croaker (Larimichthys crocea) via a B. subtilis system. Bioinformatics and circular dichroism (CD) analyses showed that Lc1687 is a novel anionic amphiphilic α-helical peptide, which was derived from the C-terminal of a Ferritin heavy subunit. The recombinant Lc1687 (named rLc1687) purified from Escherichia coli exhibited strong activities against Gram-positive (Gram+) bacterium Staphylococcus aureus, Gram-negative (Gram-) bacteria Vibrio vulnificus, V. parahaemolyticus, and Scuticociliatida. Scanning electron microscope (SEM) and transmission electron microscopy (TEM) revealed the possible function mechanisms of this peptide, which is to target and disrupt the bacterial cell membranes, including pore-forming, loss of fimbriae, and cytoplasm overflow, whereas gel retardation assay revealed that peptide Lc1687 cannot bind bacterial DNA. The peptide stability analysis showed that rLc1687 acts as a stable antimicrobial agent against Gram+ and Gram- bacteria at temperatures ranging from 25 to 100°C, pH 3-12, and UV radiation time ranging from 15 to 60 min. A hemolytic activity assay confirmed that this peptide may serve as a potential source for clinical medicine development. Taken together, Lc1687 is a novel AMP as it is a firstly confirmed Ferritin fragment with antimicrobial activity. It is also a promising agent for the development of peptide-based antibacterial and anti-parasitic therapy.

Clinical manifestations and neuron-specific enolase cerebrospinal fluid concentration in HIV/AIDS patients with cerebral toxoplasmosis

Background. Cerebral toxoplasmosis (CT) is one of the most common cause of focal neurological defi cit in HIV/ AIDS group of patients. Timely diagnosis of CT and antiparasitic therapy contribute to decrease of lethal outcomes and disability. Aim. To study neurological manifestations, cognitive functions and neuron-specifi c enolase (NSE) concentration in cerebrospinal fluid (CSF), in HIV/AIDS patients with CT. Material and methods. The 35 patients (10 females and 25 males) from 28 to 50 years old with confirmed diagnosis of HIV/AIDS-associated CT were included in the investigation group. Neurological status, cognitive function and laboratory CSF changings had been studied in prospective investigation before and during the treatment with control points in the 1st and 10th days of the observation. Results. The method of neurological manifestation of CT evaluation had been developed and implemented in practice. The association between neurological defi cit severity (movement and sensory disorders), cognitive decline and increasing CSF concentration of NSE in HIV/AIDS-associated CT was determined that demonstrates the activity of encephalitic process. Conclusion. Dynamic evaluation of NSE concentration in CSF with clinical assessment of neurological manifestation in patients with HIV/AIDS-associated CT may be used for confirmation of specific antiparasitic treatment effectiveness and for increasing clinical criteria significance.

Eosinophilic myocarditis: comprehensive update on pathophysiology, diagnosis, prognosis and management.

Hypereosinophilic syndromes are a group of disorders secondary to the accumulation of eosinophils leading to the injury of one or more organs. Among them, eosinophilic myocarditis (EM) is a rare form of inflammatory cardiomyopathy characterized by eosinophilic infiltration into myocardial tissue and subsequent release of substances with cell membrane damage and cell destruction. The degree of infiltration is thought to depend on the underlying condition, as well as the degree and duration of eosinophil exposure and ranges from mild localized disease to diffuse multifocal infiltrates associated with myocardial necrosis, thrombotic complications and endomyocardial fibrosis. The main causes of EM are hypersensitivity reactions, eosinophilic granulomatosis with polyangiitis, hypereosinophilic syndrome variants, infections and cancer. Clinical presentation can be variable, ranging from asymptomatic forms to life-threatening conditions, to chronic heart failure due to progression to chronic restrictive cardiomyopathy. Marked eosinophilia in peripheral blood, elevated serum eosinophilic cationic protein concentration and multimodality imaging may suggest the etiology of EM, but in most cases an endomyocardial biopsy must be performed to establish a definitive diagnosis. Systemic treatment varies greatly depending on the underlying cause, however the evidence of an eosinophilic infiltrate allows initiation of immunosuppressive therapy, which is the mainstay of treatment in idiopathic and in most forms of EM. Patients with helminthic infection benefit from anti-parasitic therapy, those with myeloid clone often need a tyrosine kinase inhibitor, while anticoagulant therapy should be undertaken in case of possible thrombotic complications.

Polyalthic acid and oleoresin from Copaifera trapezifolia Hayne reduce Toxoplasma gondii growth in human villous explants, even triggering an anti-inflammatory profile

Due to the lack of efficient antiparasitic therapy and vaccines, as well as emerging resistance strains, congenital toxoplasmosis is still a public health issue worldwide. The present study aimed to assess the effects of an oleoresin obtained from the species Copaifera trapezifolia Hayne (CTO), and an isolated molecule found in the CTO, ent-polyalthic acid (ent-15,16-epoxy-8(17),13(16),14-labdatrien-19-oic acid) (named as PA), against T. gondii infection. We used human villous explants as an experimental model of human maternal-fetal interface. Uninfected and infected villous explants were exposed to the treatments; the parasite intracellular proliferation and the cytokine levels were measured. Also, T. gondii tachyzoites were pre-treated and the parasite proliferation was determined. Our findings showed that CTO and PA reduced efficiently the parasite growth with an irreversible action, but without causing toxicity to the villi. Also, treatments reduced the levels of IL-6, IL-8, MIF and TNF by villi, what configures a valuable treatment option for the maintenance of a pregnancy in an infectious context. In addition to a possible direct effect on parasites, our data suggest an alternative mechanism by which CTO and PA alter the villous explants environment and then impair parasite growth, since the pre-treatment of villi resulted in lower parasitic infection. Here, we highlighted PA as an interesting tool for the design of new anti-T. gondii compounds.